Results 91 to 100 of about 6,474 (210)

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries

Harm Reduction Journal, 2020
Background This study examines the use of new psychoactive substances (NPS) and the harm reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and Georgia.
Eliza Kurcevič, Rick Lines
doaj   +1 more source

Market Analysis of Synthetic Drugs: Amphetamine-type Stimulants, New Psychoactive Substances [PDF]

, 2017
An estimated quarter of a billion people, or around 5 per cent of the global adult population, used drugs at least once in 2015. Even more worrisome is the fact that about 29.5 million of those drug users, or 0.6 per cent of the global adult population ...

core  

New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors [PDF]

, 2017
Background The continual diversification of new psychoactive substances (NPS) circumventing legislation creates a public health and law enforcement challenge, and one particularly challenged by availability on Hidden Web cryptomarkets.
Aldridge, Bancroft, Barratt, Barratt, Barratt, Barratt, Barratt, Broséus, Burns, Caudevilla, Caudevilla, Christin, Cox, Dolliver, Dolliver, Décary-Hétu, Eurobarometer 401, European Commission, European Monitoring Centre for Drugs and Drug Addiction, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), European Union, Evelyn Hearne, Evrard, Global Drug Survey, Hardy, Hearne, Jeffries, Karlsson, Kjellgren, Lavorgna, Lavorgna, Marie Claire Van Hout, Martin, Martin, Martin, Martinotti, Munksgaard, Móró, Ormsby, Orsolini, Phelps, Rhumorbarbe, Rosino, Sande, Schifano, Soska, Soussan, Soussan, Soussan, Tzanetakis, UNODC, van Amsterdam, Van Buskirk, Van Buskirk, Van Hout, Van Hout, Van Hout, Van Hout, Van Hout, Werse, Zawilska   +60 more
core   +1 more source

2024 Grade‐Specific Prevalence and Adjacent‐Grade Differences in Illicit Drug Use Among Japanese Junior and Senior High School Students

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Illicit drug use among Japanese adolescents is low overall but increases with grade, with a marked rise at the transition from grade 9 to 10. This transition represents a critical window for prevention. Abstract Aim Effective school‐based prevention of illicit drug use among adolescents requires empirical guidance on when to intervene.
Satomi Mizuno, Satoshi Inoura, Maki Kitamura, Toshihiko Matsumoto, Kunihiko Kitagaki, Akihiro Koide, Kenji Takehara, Takuya Shimane   +7 more
wiley   +1 more source

Designers Drugs—A New Challenge to Emergency Departments—An Observational Study in Poland

Medicina, 2020
Background and Objective: In the last decade, the phenomenon of using new psychoactive substances (NPS), called designer drugs, has been on rise. Though their production and marketing in Poland is prohibited, reports of the Supreme Audit Office noted ...
Rakesh Jalali, Paula Dmochowska, Izabela Godlewska, Justyna Balmas, Katarzyna Młynarska, Krzysztof Narkun, Andrzej Zawadzki, Marcin Wojnar   +7 more
doaj   +1 more source

Experimental versus theoretical log D_7.4, pK_a and plasma protein binding values for benzodiazepines appearing as new psychoactive substances [PDF]

, 2018
The misuse of benzodiazepines as new psychoactive substances is an increasing problem around the world. Basic physicochemical and pharmacokinetic data is required on these substances in order to interpret and predict their effects upon humans ...
Manchester, Kieran R., Maskell, Peter D., Waters, Laura   +2 more
core   +2 more sources

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration

British Journal of Pharmacology, Volume 183, Issue 12, Page 3173-3194, June 2026.
Cannabidiol (CBD) and cannabigerol (CBG) alleviate hepatic steatosis in obese mice by shifting energy buffering towards phosphocreatine and enhancing lysosomal lipid degradation and trafficking. These effects are associated with increased creatine kinase activity and lysobisphosphatidic acid (LBPA) levels, highlighting a previously unrecognised ...
Radka Kočvarová, Shahar Azar, Bella Agranovich, Ifat Abramovich, Saveliy Kirillov, Alina Nemirovski, Saja Baraghithy, Inbar Plaschkes, Emmanuelle Merquiol, Alexander Rouvinski, Galia Blum, Liad Hinden, Joseph Tam   +12 more
wiley   +1 more source

Updating your drugs policy to include NPS. [PDF]

, 2017
In previous briefing papers, Mentor looked at the impact of new psychoactive substances on public health and drugs education. Schools and practitioners should also update their drugs policy to take account of New Psychoactive Substances (NPS).

core  

Differential Pulse Voltammetric Analysis of the New Psychoactive Drug 3β‐(4‐Fluorobenzoyloxy)tropane (fluorotropacocaine)

Electroanalysis, Volume 38, Issue 5, May 2026.
First voltammetric characterization of fluorotropacocaine and development of a selective DPV method for real‐sample analysis. A Design of Experiments (DoE)‐optimized Florisil‐SPE cleanup enables up to 50× enrichment and sensitive detection in urine, with high selectivity against excipients, endogenous components, and co‐occurring new psychoactive ...
Giancarla Alberti, Stefano Protti, Alessandra Bonanni, Azzurra Naso, Daniele Merli   +4 more
wiley   +1 more source